ARC101 in Advanced Solid Tumors

Launched by THIRD ARC BIO · Oct 31, 2024

Keywords

ClinConnect Summary

This clinical trial, called ARC101 in Advanced Solid Tumors, is testing a new treatment called ARC101 for patients with advanced cancers, specifically those with solid tumors like ovarian or testicular cancer that have certain characteristics (Claudin 6+ cancers). The main goal of this study is to see if ARC101 is safe, how well it is tolerated by patients, and whether it can help shrink tumors. Currently, the trial is recruiting participants aged 65 to 74, and it is open to both men and women.

To be eligible for this trial, participants should have a type of cancer that is either locally advanced or has spread to other parts of the body, and their disease should be measurable using specific medical guidelines. They should also be in good general health, with a performance status rated between 0-1 (meaning they are fully active or only slightly limited in their activities). However, there are some exclusions, such as having certain active diseases or recent serious health issues. If you join the study, you can expect to receive the study drug and undergo regular check-ups to monitor your health and the effects of the treatment. This trial is an important step in exploring new options for patients with advanced cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+ cancers
• • Measurable or evaluable disease, per RECIST v1.1
• • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• • Adequate organ function
• Exclusion Criteria:
• • Active CNS involvement
• • Malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study drug.
• • Presence of uncontrolled ascites
• • Toxicity related to prior anticancer therapy that has not returned to Grade ≤1 or baseline levels
• • Clinically significant pulmonary compromise
• • Active autoimmune disease within 12 months prior to first dose of study drug.
• • Female participant who is pregnant, breastfeeding, or plans to become pregnant or male participant who plans to father a child either while enrolled or within 90 days after the final administration of study drug.